Core F: Biomarker Core

核心 F：生物标志物核心

• 批准号: 10663303
• 负责人: Nicholas M Kanaan
• 金额: $ 33.81万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663303
• 关键词: Alzheimer' s Disease; Alzheimer' s disease related dementia; Amyloid; Amyloid beta-42; Amyloid beta-Protein; Antibodies; Automobile Driving; Biological Assay; Biological Markers; Blood; Brain; Clinical; Clinical Management; Clinical Research; Clinical Trials; Collaborations; Collection; Coupled; Data; Databases; Dementia; Development; Diagnosis; Diagnostic; Disease; Disease Progression; Educational Activities; Enzyme-Linked Immunosorbent Assay; Ethnic Population; Evaluation; Faculty; Future; Goals; Health Professional; Interleukin-10; Interleukin-6; Light; Longitudinal cohort; Magnetic Resonance Imaging; Mass Spectrum Analysis; Measurement; Measures; Michigan; Modality; Molecular Profiling; Neuropsychology; Onset of illness; Patient Recruitments; Patients; Peripheral; Physicians; Plasma; Positron-Emission Tomography; Proteomics; Reagent; Research; Research Personnel; Research Support; Resources; Sampling; Scientist; Shapes; Students; System; TNF gene; Technology; Time; Translational Research; Universities; blood-based biomarker; cardiovascular risk factor; clinical center; clinical practice; cost; data management; diagnostic accuracy; disease heterogeneity; education research; genomic data; health training; improved; innovation; neurofilament; neuroimaging; neuropathology; novel; novel marker; patient population; precision medicine; racial population; single molecule; targeted biomarker; tau Proteins

ABSTRACT – CORE F: BIOMARKER CORE Biomarkers are becoming instrumental components of effective clinical management and trial coordination for Alzheimer’s disease and related dementias (ADRD), and will be required to enable precision medicine approaches to diagnosis and treatment. The primary functions of the newly added Biomarker Core (BC) of the Michigan Alzheimer’s Disease Research Center (MADRC) will be to facilitate innovative research into established and novel blood biomarkers, and provide expertise and access to biomarker assay technologies for investigators at the University of Michigan, Michigan State University, Wayne State University, as well as other ADRCs. The overall goal of the BC is to use cutting-edge ultrasensitive ELISA and quantitative mass spectrometry (MS) approaches to measure biomarkers in blood, identify and build novel blood-based biomarker assays, and integrate biomarkers with clinical measures of disease. We will leverage MADRC resources from ongoing and future efforts to achieve this goal and promote studies that align with the MADRC’s central theme to identify, understand and modulate the many factors beyond β-amyloid contributing to ADRD. The diverse patient population in the MADRC’s longitudinal cohort and other ongoing clinical research efforts, coupled with the ability to develop novel biomarker assays, will significantly enhance the ability of the BC to focus on unique questions regarding the extent to which current and novel biomarker targets enhance diagnostic accuracy, and track disease progression and predictability over time in multiple patient populations, including underrepresented racial/ethnic groups. The BC will pursue the following five aims: 1) provide measurements of established blood biomarkers, 2) develop and implement novel biomarker assays, 3) facilitate integration of blood biomarkers with established clinical practices to advance translational research, 4) contribute blood biomarker data to the National Alzheimer’s Coordinating Center, and 5) educate and train health care professionals, scientists and students in the use of biomarker assays. The BC goals and aims will be achieved by working closely with the MADRC Clinical Core, Data Management and Statistical Core, Neuroimaging Core, Neuropathology Core, and Research Education Component. Through these efforts, the BC will markedly enhance research supported by the MADRC, leading to a sustained and significant impact for the field as we build a comprehensive assessment of the diagnostic and the predictive utility of blood-based biomarker profiles. We will also interface with other ADRCs and investigators to help shape an evolving clinical landscape for dementia evaluation and treatment.

摘要 - 核心F：生物标志物核心 生物标志物已成为有效的临床管理和试验协调的工具组件 阿尔茨海默氏病和相关痴呆症（ADRD），将被要求启用精确医学 诊断和治疗方法。新添加的生物标志物核心（BC）的主要功能 密歇根州阿尔茨海默氏病研究中心（MADRC）将促进创新研究 已建立和新颖的血液生物标志物，并提供专业知识和使用生物标志物测定技术 密歇根大学密歇根州立大学，韦恩州立大学的调查员以及 其他ADRC。卑诗省的总体目标是使用尖端的超敏感ELISA和定量质量 测量血液中生物标志物，识别和构建新型血液的光谱法（MS）方法 生物标志物测定和综合疾病临床测量的生物标志物。我们将利用Madrc 从持续不断的和未来的努力来实现这一目标并促进与与人保持一致的研究的资源 MADRC的中心主题是识别，理解和调节β-淀粉样蛋白以外的许多因素 到Adrd。 Madrc纵向队列和其他正在进行的临床的潜水员患者人数 研究工作，再加上开发新型生物标志物测定的能力，将显着增强 卑诗省专注于有关当前和新颖的生物标志物程度的独特问题 目标提高诊断准确性，并在多个方面跟踪疾病的发展和可预测性 患者人口，包括代表性不足的种族/族裔群体。卑诗省将追求以下五个 目的：1）提供既定的血液生物标志物的测量，2）开发和实施新型生物标志物 测定，3）促进血液生物标志物与已建立的临床实践的整合以推动翻译 研究，4）向国家阿尔茨海默氏症协调中心贡献血液生物标志物数据，5）教育 以及培训医疗保健专业人员，科学家和学生使用生物标志物测定法。卑诗省的目标和 将通过与MADRC临床核心，数据管理和统计的紧密合作来实现目标 核心，神经成像核心，神经病理学核心和研究教育部分。通过这些努力， 卑诗省将明显增强马德拉克支持的研究，从而导致持续而重要的研究 当我们对诊断和预测效用进行全面评估时，对该领域的影响 基于血液的生物标志物谱。我们还将与其他ADRC和调查人员进行交互，以帮助塑造 不断发展的临床景观用于痴呆评估和治疗。